<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959932</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHR-REXC-03-EU</org_study_id>
    <secondary_id>ZRHR-REXC-03-EU</secondary_id>
    <nct_id>NCT01959932</nct_id>
  </id_info>
  <brief_title>Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.</brief_title>
  <official_title>A Randomized, Controlled, Open-label, 3-arm Parallel Group, Single-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smoking, Healthy Subjects Switching to the Tobacco Heating System 2.2 (THS 2.2) or Smoking Abstinence, Compared to Continuing to Use Conventional Cigarettes, for 5 Days in Confinement.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating
      System 2.2 (THS 2.2) for 5 days by adult healthy smokers results in a reduction in the levels
      of biomarkers of exposure (BoExp) for selected harmful and potentially harmful constituents
      (HPHCs) compared to smoking conventional cigarettes (CC) and smoking abstinence (SA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of S-phenylmercapturic Acid (S-PMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Carboxyhemoglobin (COHb)</measure>
    <time_frame>5 days</time_frame>
    <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Tobacco Heating System (THS 2.2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoking abstinence (SA)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Abstinence from smoking for 5 days in confinement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco Heating System (THS 2.2)</intervention_name>
    <description>THS 2.2 ad libitum for 5 days in confinement</description>
    <arm_group_label>Tobacco Heating System (THS 2.2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smoking abstinence (SA)</intervention_name>
    <description>SA for 5 days in confinement</description>
    <arm_group_label>Smoking abstinence (SA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette (CC)</intervention_name>
    <description>Subject's own preferred brand of CC ad libitum for 5 days in confinement</description>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Caucasian.

          -  Current healthy smoker as judged by the Principal Investigator.

          -  Subject has smoked at least 10 commercially available non-menthol CCs per day (no
             brand restrictions) for the last 4 weeks.

          -  Subject has smoked for at least the last 3 consecutive years.

          -  Subject does not plan to quit smoking in the next 3 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of the
             medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2)
             or cytochrome P450 2A6 (CYP2A6) activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarzyna Jarus-Dziedzic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioVirtus Research Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. z o.o.</name>
      <address>
        <city>Kajetany</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>August 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2016</results_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Candidate Modified Risk Tobacco Product</keyword>
  <keyword>Conventional cigarettes</keyword>
  <keyword>Reduced exposure</keyword>
  <keyword>Confinement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 29 June 2013
At admission (Day -2), all the subjects performed a product trial of the THS 2.2. During the baseline period, they continued smoking their single preferred brand of CC. Then, on Day 0, subjects were randomized to one of the 3 study arms (THS 2.2, CC or SA) in a 2:1:1 ratio.</recruitment_details>
      <pre_assignment_details>Enrolled and randomized population = 160 subjects
80 subjects in THS 2.2
41 subjects in CC
39 subjects in SA
Number of subjects enrolled but NOT randomized (who tried the THS 2.2 at Day -2) = 9</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tobacco Heating System (THS 2.2)</title>
          <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
        </group>
        <group group_id="P2">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
        <group group_id="P3">
          <title>Smoking Abstinence (SA)</title>
          <description>Abstinence from smoking for 5 days in confinement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study population consisted of all the randomized subjects who had at least 1 post randomization product use experience (THS 2.2 or CC arms), and 1 valid biomarker of exposure (BoExp) measurement.
160 randomized subjects: 80 in THS 2.2, 41 in CC and 39 in SA
159 completers: 1 subject (THS 2.2 arm) voluntarily withdrew on Day 3</population>
      <group_list>
        <group group_id="B1">
          <title>Tobacco Heating System (THS 2.2)</title>
          <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
        </group>
        <group group_id="B2">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
        <group group_id="B3">
          <title>Smoking Abstinence (SA)</title>
          <description>Abstinence from smoking for 5 days in confinement</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Between 21 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="9.40"/>
                    <measurement group_id="B2" value="32.6" spread="10.06"/>
                    <measurement group_id="B3" value="33.6" spread="11.51"/>
                    <measurement group_id="B4" value="34.3" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily CC consumption at Screening</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 to 19 cig/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 19 cig/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid biomarker of exposure (BoExp) measurement (THS 2.2, CC, SA arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Tobacco Heating System (THS 2.2)</title>
            <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
          <group group_id="O3">
            <title>Smoking Abstinence (SA)</title>
            <description>Abstinence from smoking for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid biomarker of exposure (BoExp) measurement (THS 2.2, CC, SA arms).</population>
          <units>pg/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.05" lower_limit="173.23" upper_limit="217.38"/>
                    <measurement group_id="O2" value="2314.37" lower_limit="1975.39" upper_limit="2711.52"/>
                    <measurement group_id="O3" value="168.01" lower_limit="142.88" upper_limit="197.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for THS 2.2 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for THS 2.2 and CC respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on MHBMA levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>8.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.89</ci_lower_limit>
            <ci_upper_limit>10.20</ci_upper_limit>
            <estimate_desc>LS mean ratio THS 2.2:CC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Tobacco Heating System (THS 2.2)</title>
            <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
          <group group_id="O3">
            <title>Smoking Abstinence (SA)</title>
            <description>Abstinence from smoking for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
          <units>ng/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.87" lower_limit="376.74" upper_limit="422.30"/>
                    <measurement group_id="O2" value="958.03" lower_limit="884.99" upper_limit="1037.09"/>
                    <measurement group_id="O3" value="242.56" lower_limit="223.64" upper_limit="263.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for THS 2.2 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for THS 2.2 and CC respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on 3-HPMA levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS mean ratio</param_type>
            <param_value>41.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.75</ci_lower_limit>
            <ci_upper_limit>45.91</ci_upper_limit>
            <estimate_desc>LS mean ratio THS 2.2:CC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Tobacco Heating System (THS 2.2)</title>
            <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
          <group group_id="O3">
            <title>Smoking Abstinence (SA)</title>
            <description>Abstinence from smoking for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
          <units>pg/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.51" lower_limit="151.82" upper_limit="178.25"/>
                    <measurement group_id="O2" value="2748.16" lower_limit="2457.56" upper_limit="3073.13"/>
                    <measurement group_id="O3" value="153.66" lower_limit="137.03" upper_limit="172.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for THS 2.2 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for THS 2.2 and CC respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on S-PMA levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>5.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.21</ci_lower_limit>
            <ci_upper_limit>6.87</ci_upper_limit>
            <estimate_desc>LS mean ratio THS 2.2:CC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Carboxyhemoglobin (COHb)</title>
        <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
        <group_list>
          <group group_id="O1">
            <title>Tobacco Heating System (THS 2.2)</title>
            <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
          <group group_id="O3">
            <title>Smoking Abstinence (SA)</title>
            <description>Abstinence from smoking for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Carboxyhemoglobin (COHb)</title>
          <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (if randomized to THS 2.2 or CC) and had at least 1 valid BoExp measurement (THS 2.2, CC, SA arms).</population>
          <units>% of saturation of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="1.02" upper_limit="1.11"/>
                    <measurement group_id="O2" value="4.53" lower_limit="4.29" upper_limit="4.77"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.93" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for THS 2.2 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for THS 2.2 and CC respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on COHb levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>23.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.00</ci_lower_limit>
            <ci_upper_limit>24.99</ci_upper_limit>
            <estimate_desc>LS mean ratio THS 2.2:CC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the informed consent form (ICF) signature until the end of the safety follow-up period (7 days after discharge of the subject).</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 169 subjects: 160 randomized subjects (80 in THS 2.2, 41 in CC and 39 in SA) and 9 subjects exposed to THS 2.2 from the product trial on Day -2 but not randomized.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tobacco Heating System (THS 2.2)</title>
          <description>Ad libitum use of THS 2.2 for 5 days in confinement</description>
        </group>
        <group group_id="E2">
          <title>Smoking Abstinence (SA)</title>
          <description>Abstinence from smoking for 5 days in confinement</description>
        </group>
        <group group_id="E3">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
        <group group_id="E4">
          <title>Enrolled But Not Randomized</title>
          <description>Subjects who tried the THS 2.2 at Admission (Day -2) but were not randomized in 1 of the 3 arms as they were back-up subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Spirometry abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belongs to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle HAZIZA, PhD</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2625</phone>
      <email>Christelle.Haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

